Abstract:The combination of paclitaxel (PTX) with other chemotherapy drugs (e.g., gemcitabine, GEM) or genetic drugs (e.g., siRNA) has been shown to enhance therapeutic efficacy against tumors, reduce individual drug dosages, and prevent drug resistance associated with single-drug treatments. However, the varying solubility of chemotherapy drugs and genetic drugs presents a challenge in co-delivering these agents. In this study, nanoparticles loaded with PTX were prepared using the biodegradable polymer material poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) (PHBHHx). These nanoparticles were surface-modified with target proteins (Affibody molecules) and RALA cationic peptides to create core-shell structured microspheres with targeted and cationic functionalization. A three-drug co-delivery system (PTX@PHBHHx-ARP/siRNAGEM) were developed by electrostatically adsorbing siRNA chains containing GEM onto the microsphere surface. The encapsulation efficiency of PTX in the nanodrug was found to be 81.02%, with a drug loading of 5.09%. The chemogene adsorption capacity of siRNAGEM was determined to be 97.3%. Morphological and size characterization of the nanodrug revealed that PTX@PHBHHx-ARP/siRNAGEM is a rough-surfaced microsphere with a particle size of approximately 150 nm. This nanodrug exhibited targeting capabilities toward BT474 cells with HER2 overexpression while showing limited targeting ability toward MCF-7 cells with low HER2 expression. Results from the MTT assay demonstrated that PTX@PHBHHx-ARP/siRNAGEM exhibits high cytotoxicity and excellent combination therapy efficacy compared to physically mixed PTX/GEM/siRNA. Additionally, Western blot analysis confirmed that siRNA-mediated reduction of Bcl-2 expression significantly enhanced cell apoptosis mediated by PTX or GEM in tumor cells, thereby increasing cell sensitivity to PTX and GEM. This study presents a novel targeted nanosystem for the co-delivery of chemotherapy drugs and genetic drugs.

Pancreatic Cancer: Targeted Co‐delivery of PTX and TR3 Sirna by PTP Peptide Modified Dendrimer for the Treatment of Pancreatic Cancer (small 2/2017)

Targeted Co-Delivery of Ptx and Tr3 Sirna by Ptp Peptide Modified Dendrimer for the Treatment of Pancreatic Cancer

Enhancement of Antitumor Efficacy of Paclitaxel-Loaded PEGylated Liposomes by N,N-Dimethyl Tertiary Amino Moiety in Pancreatic Cancer

Targeted co‐delivery of PTX and TR3 siRNA by PTP peptide modified dendrimer for the treatment of pancreatic cancer

Co-Delivery of Paclitaxel Prodrug, Gemcitabine and Porphine by Micelles for Pancreatic Cancer Treatment Via Chemo-Photodynamic Combination Therapy

Toward targeted therapy in chemotherapy-resistant pancreatic cancer with a smart triptolide nanomedicine

Targeted Codelivery Of Docetaxel And Atg7 Sirna For Autophagy Inhibition And Pancreatic Cancer Treatment

Co-delivery of Paclitaxel and Anti-Vegf Sirna by Tripeptide Lipid Nanoparticle to Enhance the Anti-Tumor Activity for Lung Cancer Therapy.

Cascade Drug Delivery Through Tumor Barriers of Pancreatic Cancer Via Ultrasound in Combination with Functional Microbubbles.

Membrane-camouflaged supramolecular nanoparticles for co-delivery of chemotherapeutic and molecular-targeted drugs with siRNA against patient-derived pancreatic carcinoma

Drug delivery particles for targeted imaging-guided photothermal/chemotherapy synergy cancer therapy

Targeted PHA Microsphere-Loaded Triple-Drug System with Sustained Drug Release for Synergistic Chemotherapy and Gene Therapy

FDA-Approved Hydrogel-Mediated In Situ Sonodynamic and Chemotherapeutic Therapy for Pancreatic Cancer

Sequentially Triggered Nanoparticles with Tumor Penetration and Intelligent Drug Release for Pancreatic Cancer Therapy

TMTP1-Modified, Tumor Microenvironment Responsive Nanoparticles Co-Deliver Cisplatin and Paclitaxel Prodrugs for Effective Cervical Cancer Therapy

Semiconducting polymer nano-radiopharmaceutical for combined radio-photothermal therapy of pancreatic tumor

Stromal Modulation and Treatment of Metastatic Pancreatic Cancer with Local Intraperitoneal Triple Mirna/sirna Nanotherapy

An intracellular enzyme-responsive polymeric prodrug with synergistic effect of chemotherapy and two-photon photodynamic therapy

Transcytosable Peptide-Paclitaxel Prodrug Nanoparticle for Targeted Treatment of Triple-Negative Breast Cancer

Porphyrin Centered Paclitaxel Tetrameric Prodrug Nanoassemblies as Tumor‐Selective Theranostics for Synergized Breast Cancer Therapy

Natural Particulates Inspired Specific-Targeted Codelivery of Sirna and Paclitaxel for Collaborative Antitumor Therapy